0001214659-18-000708.txt : 20180129 0001214659-18-000708.hdr.sgml : 20180129 20180129180017 ACCESSION NUMBER: 0001214659-18-000708 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180126 FILED AS OF DATE: 20180129 DATE AS OF CHANGE: 20180129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Christensen Jamie CENTRAL INDEX KEY: 0001599324 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35921 FILM NUMBER: 18556998 MAIL ADDRESS: STREET 1: C/O MIRATI THERAPEUTICS, INC. STREET 2: 9393 TOWNE CENTRE DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirati Therapeutics, Inc. CENTRAL INDEX KEY: 0001576263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462693615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-332-3410 MAIL ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 marketforms-40853.xml PRIMARY DOCUMENT X0306 4 2018-01-26 0001576263 Mirati Therapeutics, Inc. MRTX 0001599324 Christensen Jamie C/O MIRATI THERAPEUTICS, INC. 9393 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 false true false false SVP, Chief Scientific Officer Common Stock 2018-01-26 4 M false 12500 5.40 A 15377 D Common Stock 2018-01-26 4 S false 12500 26.1138 D 2877 D Employee Stock Option (Right to Buy) 5.4 2018-01-26 4 M false 12500 0 D 2027-01-25 Common Stock 12500 37500 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2017. 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. This transaction was executed in multiple trades at prices ranging from $25.85 to $26.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. /s/ Vickie Reed, Attorney-in-Fact 2018-01-29